Instrument NameGsk Plc ADRInstrument Symbol(GSK-N)

Instrument ExchangeNYSE

‘ESG is becoming a bit toxic. Nobody really knows what it is and what it includes or doesn’t include,’ says François Bourdon, managing partner of Nordis Capital

The Federal Trade Commission is challenging patents on 20 brand-name drugs, including the blockbuster weight-loss injection Ozempic

Wall Street analysts who watch the cancer drug developer closely think it could rocket higher.

These stocks could rocket higher, but they also present significant risks.

Several well-regarded funds run by famous billionaire investors bought shares of 23andMe during the last three months of 2023.

/CNW/ - Find Therapeutics Inc., a biopharmaceutical company focused on the development of innovative therapies for autoimmune diseases, today announced that...

The renowned brokerage firm weighed in on its top stock picks from the European market, which could offer investors better value than the outsized GRANOLAS group of equities at current levels.

GSK's stock has been a poor performer for years. But recently, the pharma stock keeps setting new 52-week highs, thanks to its blockbuster vaccines.

A survey of North American equities heading in both directions

Growth stocks are getting ready for a comeback year in 2024, and these two under-the-radar stocks have solid financials and significant upside potential.

Unlike many of its peers, GSK just reported a big year-over-year jump in vaccine sales - and there's more growth to come, as the pharmaceutical company expands both its pipeline and the geographical reach for its vaccines.

The world is a big place, and many great companies are based outside our U.S. borders.

Pharma stock GSK is a remedy for the winter blahs with a low beta, a high yield, and value for investors. Sales of new drug Arexvy underpin results.

Moderna stock soared early in the pandemic.

Viatris, GSK, and Organon are all trading at less than 7 times earnings.

GSK offers a robust dividend yield, but that's not the only thing to consider.

U.S. health officials are recommending that babies get a recently approved drug to protect them against a respiratory virus

The era of the giant pharmaceutical conglomerate is coming to a close, but consumer-focused Haleon stock looks set to deliver healthy returns through long-term economic cycles.

GSK stock could be a bargain.

The company had disappointing trial news for one of its lead therapies.

These pharmaceutical companies all combine relatively high dividends with safe payout ratios.

You don't need a treasure chest full of cash to begin building wealth on Wall Street.

Which of these AI-powered drugmakers is the better buy right now?

/CNW/ - GSK plc (LSE: GSK) (NYSE: GSK) and BELLUS Health Inc. (TSX: BLU) NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a...

Up more than 25% in the last nine months, U.K. pharmaceutical company GSK PLC is slowly regaining favor with investors after the GSK lawsuit.